APOBEC2 is a member of the apolipoprotein B mRNA editing enzyme family with cytidine deaminase activity, though its physiological substrate remains unclear 1. Unlike APOBEC1 (RNA editing) and AID (antibody diversification), APOBEC2 appears to have specialized functions distinct from canonical deamination roles 2. Despite displaying low intrinsic deaminase activity, APOBEC2 is primarily expressed in skeletal and cardiac muscle 3. In muscle biology, APOBEC2 acts as a negative regulator of myoblast differentiation; APOBEC2-deficient mice show accelerated myogenic progression and enhanced muscle regeneration following injury, suggesting a role in controlling the timing of myoblast-to-myotube transition 3. In hepatic contexts, APOBEC2 expression is regulated by pro-inflammatory cytokines TNF-α and IL-1β through NF-κB signaling 4, and HBV infection upregulates APOBEC2 via miR-122 suppression, linking APOBEC2 to hepatocarcinogenesis through tumor suppressor gene mutations 5. In gastric adenocarcinoma, APOBEC2 downregulation associates with neutrophil infiltration and worse prognosis in chemotherapy-treated patients, though it is not an independent prognostic factor 6. In oculopharyngeal muscular dystrophy, elevated plasma APOBEC2 correlates with muscle degeneration severity 7. Gene-targeting studies confirm APOBEC2 is dispensable for basic development and fertility 8.